Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Operating Expenses: 2018-2025

Historic Operating Expenses for Bicycle Therapeutics (BCYC) over the last 8 years, with Sep 2025 value amounting to $77.3 million.

  • Bicycle Therapeutics' Operating Expenses rose 16.18% to $77.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $318.4 million, marking a year-over-year increase of 36.43%. This contributed to the annual value of $245.1 million for FY2024, which is 13.01% up from last year.
  • According to the latest figures from Q3 2025, Bicycle Therapeutics' Operating Expenses is $77.3 million, which was down 13.67% from $89.5 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Operating Expenses registered a high of $89.5 million during Q2 2025, and its lowest value of $17.8 million during Q1 2021.
  • For the 3-year period, Bicycle Therapeutics' Operating Expenses averaged around $64.5 million, with its median value being $59.6 million (2023).
  • Data for Bicycle Therapeutics' Operating Expenses shows a peak YoY soared of 76.08% (in 2022) over the last 5 years.
  • Over the past 5 years, Bicycle Therapeutics' Operating Expenses (Quarterly) stood at $21.8 million in 2021, then spiked by 62.40% to $35.4 million in 2022, then spiked by 68.28% to $59.6 million in 2023, then climbed by 19.82% to $71.4 million in 2024, then grew by 16.18% to $77.3 million in 2025.
  • Its last three reported values are $77.3 million in Q3 2025, $89.5 million for Q2 2025, and $80.2 million during Q1 2025.